Literature DB >> 2941278

Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.

T Bergan, S B Thorsteinsson, I M Kolstad, S Johnsen.   

Abstract

The pharmacokinetics of ciprofloxacin were evaluated after increasing single oral doses of 100, 250, 500 and 1000 mg, and an intravenous dose of 100 mg given to each of 12 healthy volunteers (6 females and 6 males). Concentrations in serum and urine were determined by microbiological assay. The rise in peak serum concentrations and the values of the total area under the serum concentration curve were proportional to the increase in the oral doses. As the oral dose increased a slight increase was observed in the apparent time lag before absorption from 0.34 h after 100 mg to 0.53 h after 1000 mg. The serum half-life after the intravenous dose was 3.2 h. After the oral doses shorter apparent half-life values were observed. The intravenous dose showed an elimination phase distribution volume of 2.76 l/kg and total body clearance of 40.7 l/h. The total urinary excretion was 42.2 +/- 15.6% of the dose after the intravenous dose; the figure was lower after the oral doses. The bioavailability of the 100 mg oral dose was 83.7% as calculated from the value of the total area under the serum curve after the same oral and intravenous dose in all 12 subjects. Ciprofloxacin thus demonstrates normal linear pharmacokinetics, the rise in serum concentrations being proportional to the dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941278     DOI: 10.1007/bf02013984

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  15 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

4.  Multiple-dose ciprofloxacin kinetics in normal subjects.

Authors:  G E Aronoff; C H Kenner; R S Sloan; S T Pottratz
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

5.  A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.

Authors:  L Shrire; J Saunders; R Traynor; H J Koornhof
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  The pharmacokinetics of ciprofloxacin in patients with impaired renal function.

Authors:  J Boelaert; Y Valcke; M Schurgers; R Daneels; M Rosseneu; M T Rosseel; M G Bogaert
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

8.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.

Authors:  D C Brittain; B E Scully; M J McElrath; R Steinman; P Labthavikul; H C Neu
Journal:  J Clin Pharmacol       Date:  1985-03       Impact factor: 3.126

10.  Dose dependence in human absorption of aminopenicillins.

Authors:  J Sjövall
Journal:  Infection       Date:  1979       Impact factor: 3.553

View more
  17 in total

1.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Pharmacokinetics of ciprofloxacin in peripheral lymph and skin blisters.

Authors:  T Bergan; A Engeset; W Olszewski; N Ostby; R Solberg
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

Review 5.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

6.  Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.

Authors:  C A Hirata; D R Guay; W M Awni; D J Stein; P K Peterson
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 7.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection.

Authors:  W Witte; H Grimm
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.